ArriVent BioPharma sets $250M ATM stock capacity
ArriVent BioPharma, Inc. filed a prospectus supplement tied to its existing at-the-market equity offering program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
ArriVent BioPharma, Inc. filed a prospectus supplement tied to its existing at-the-market equity offering program. Under this supplement, the company may offer and sell shares of its common stock with an aggregate offering price of up to $250,000,000 from time to time through Jefferies LLC as sales agent.
The at-the-market sales are made under an Open Market Sale Agreement dated February 3, 2025, and are covered by ArriVent’s automatic shelf registration statement on Form S-3ASR, which became effective upon filing. The company also filed the sales agreement and related legal opinions as exhibits.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
ATM capacity: $250,000,000 aggregate offering price
Shelf registration file number: 333-284661
Open Market Sale Agreement date: February 3, 2025
3 metrics
ATM capacity
$250,000,000 aggregate offering price
Maximum common stock ArriVent may sell under the ATM Program
Shelf registration file number
333-284661
Automatic shelf registration statement on Form S-3ASR
Open Market Sale Agreement date
February 3, 2025
Date of sales agreement between ArriVent and Jefferies LLC
Key Terms
at the market offering, prospectus supplement, automatic shelf registration statement, Form S-3ASR, +2 more
6 terms
at the market offering financial
"with respect to the Company’s existing “at the market offering” program (the “ATM Program”)."
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
prospectus supplement regulatory
"filed with the Securities and Exchange Commission ... a prospectus supplement (the “Prospectus Supplement”)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
automatic shelf registration statement regulatory
"filed pursuant to the automatic shelf registration statement on Form S-3ASR"
An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.
Form S-3ASR regulatory
"automatic shelf registration statement on Form S-3ASR (File No. 333-284661)"
Form S-3ASR is a type of SEC registration that lets large, well-known public companies pre-register securities so they can be sold quickly when needed, similar to having a pre-approved credit line they can draw on at short notice. For investors, it matters because it signals a company's readiness to raise cash fast, which can affect share supply and price (dilution) and reveal how easily the company can fund growth or handle short-term needs.
Open Market Sale Agreement financial
"through Jefferies LLC as sales agent, pursuant to the Open Market Sale , dated as of February 3, 2025"
A contract that lets a shareholder or issuer authorize a broker to sell stock into the public market over time rather than to one specific buyer. Think of it like hiring a salesperson to quietly sell items from your garage in small batches so you don’t crash the price; for investors it matters because it increases supply and liquidity, can put downward pressure on the share price, and signals an upcoming flow of shares into the market.
Emerging Growth Company regulatory
"Emerging Growth Company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ArriVent BioPharma (AVBP) announce regarding its stock offering?
ArriVent BioPharma filed a prospectus supplement for its existing at-the-market stock offering program. This allows the company to sell common shares over time through Jefferies LLC under a previously signed Open Market Sale Agreement and an effective automatic shelf registration.
How large is ArriVent BioPharma’s at-the-market program described in this 8-K?
The prospectus supplement permits ArriVent to sell common stock with an aggregate offering price of up to $250,000,000. These shares may be issued from time to time through Jefferies LLC acting as sales agent under the company’s existing Open Market Sale Agreement.
Which bank is acting as sales agent for ArriVent BioPharma’s ATM offering?
Jefferies LLC is the sales agent for ArriVent BioPharma’s at-the-market offering program. The program operates under an Open Market Sale Agreement dated February 3, 2025, and is supported by an automatic shelf registration statement on Form S-3ASR.
What SEC registration statement covers ArriVent BioPharma’s ATM sales?
The at-the-market sales are covered by ArriVent BioPharma’s automatic shelf registration statement on Form S-3ASR, File No. 333-284661. This registration statement became effective upon filing and supports issuance of common stock under the prospectus supplement.
What legal documents did ArriVent BioPharma file with this 8-K?
ArriVent filed the Open Market Sale Agreement with Jefferies LLC as an exhibit, incorporated by reference from its Form S-3ASR. It also filed a legal opinion from Mintz, Levin and a related consent, along with the cover page interactive data file.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates